Jeffries', if that is indeed who has been appointed as it's...

Jeffries', if that is indeed who has been appointed as it's never been confirmed, role is to advise us on corporate transactions and strategy, not licensing transactions. I find this interesting because as Jon has stated many times, and most recently in the webinar, is that they will not be sitting on their hands in getting this drug to the market- speed to the market is a priority. Given that, a decision therefore needs to be made in the next 6 months on how NNZ-2591 will progress in PM.

Our corporate advisor wont be advising on licencising deals- Jon and Gerry will drive this. Its makes for interesting internal discussions at Neuren as on one hand you have a corporate advisor who is likely testing the takeover landscape and liasing with interested parties on such, and on the other hand our CEO and VP would be fielding interst in relation to partnering options. Interesting times indeed.